Safety, Biomarker Responses, and Preliminary Efficacy Following a Single Intrathecal Dose of RAG-17, a Novel siRNA Therapeutic for SOD1-ALS: Results from an Ongoing Phase I/II Study (Poster)
Event: 2026 American Academy of Neurology (AAN) Annual Meeting（Chicago） View Poster View News: Ractigen Therapeutics…
Ractigen04/19/2026
